199 related articles for article (PubMed ID: 37322479)
1. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.
Nishikubo K; Ohgaki R; Liu X; Okanishi H; Xu M; Endou H; Kanai Y
Cancer Cell Int; 2023 Jun; 23(1):116. PubMed ID: 37322479
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation.
Zhou X; Ohgaki R; Jin C; Xu M; Okanishi H; Endou H; Kanai Y
J Pharmacol Sci; 2024 Mar; 154(3):182-191. PubMed ID: 38395519
[TBL] [Abstract][Full Text] [Related]
3. Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.
Okanishi H; Ohgaki R; Xu M; Endou H; Kanai Y
Cancer Metab; 2022 Nov; 10(1):18. PubMed ID: 36357940
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
Chen YH; Chen YC; Lin CC; Hsieh YP; Hsu CS; Hsieh MC
Cancer Manag Res; 2020; 12():4645-4665. PubMed ID: 32606957
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M; Koh I; Nakamoto K; Nosaka S; Tomono K; Sugimoto J; Kudo Y
Anticancer Res; 2023 Jun; 43(6):2509-2517. PubMed ID: 37247931
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
[TBL] [Abstract][Full Text] [Related]
8. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.
Shi Z; Kaneda-Nakashima K; Ohgaki R; Xu M; Okanishi H; Endou H; Nagamori S; Kanai Y
Sci Rep; 2023 Aug; 13(1):13943. PubMed ID: 37626086
[TBL] [Abstract][Full Text] [Related]
10. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
11. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence.
Bo T; Kobayashi S; Inanami O; Fujii J; Nakajima O; Ito T; Yasui H
Transl Oncol; 2021 Nov; 14(11):101212. PubMed ID: 34461558
[TBL] [Abstract][Full Text] [Related]
12. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
13. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Kaira K; Sunose Y; Ohshima Y; Ishioka NS; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Yamaguchi A; Segawa A; Ide M; Mori M; Oyama T; Takeyoshi I
BMC Cancer; 2013 Oct; 13():482. PubMed ID: 24131658
[TBL] [Abstract][Full Text] [Related]
15. Heptadecanoic Acid, an Odd-Chain Fatty Acid, Induces Apoptosis and Enhances Gemcitabine Chemosensitivity in Pancreatic Cancer Cells.
Kim HY; Moon JY; Cho SK
J Med Food; 2023 Mar; 26(3):201-210. PubMed ID: 36716276
[TBL] [Abstract][Full Text] [Related]
16. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
Bhutia YD; Hung SW; Patel B; Lovin D; Govindarajan R
Cancer Res; 2011 Mar; 71(5):1825-35. PubMed ID: 21343396
[TBL] [Abstract][Full Text] [Related]
17. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.
Park M; Upton D; Blackmon M; Dixon V; Craver S; Neal D; Perkins D
BMC Complement Altern Med; 2018 Feb; 18(1):71. PubMed ID: 29463243
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
20. Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine.
Wang Z; Luo G; Qiu Z
Oncol Lett; 2020 Mar; 19(3):1999-2004. PubMed ID: 32194695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
